Business
-
Discovery Laboratories has announce the launch of its Afectair airway connector for the delivery of aerosolized medications to infants in neonatal or pediatric intensive care units. The disposable device enables delivery of aerosolized drugs to… Read more . . .
-
Acorda Therapeutics says that it has completed its acquisition of Neuronex, including Neuronex’s diazepam nasal spray formulation, for $6.8 million. The company also announced that it plans to submit a 505(b)(2) NDA in 2013 for… Read more . . .
-
Matrixx Initiatives has voluntarily recalled a single lot of Zicam Extreme Congestion Relief nasal gel spray due to contamination with Burkholderia cepacia in a single sample. Zicam is a homeopathic product available over the counter… Read more . . .
-
SkyePharma has announced that AstraZeneca will pay $8 million in January 2013 “to settle certain disputes” resulting from AZ’s termination of their licensing deal for the Pulmicort MDI. The deal was terminated after AZ discontinued… Read more . . .
-
Aptar Pharma has “significantly increased” the production capacity at its facility in Eigeltingen, Germany for nasal delivery pumps for preservative free formulations, the company says, in order to meet continuously rising demand for preservative free… Read more . . .
-
Aradigm Corporation has agreed to sell 50 million shares of common stock at $0.12 per share to two existing shareholders, generating net proceeds of approximately $5.6 million after fees and expenses. According to Aradigm President… Read more . . .
-
Almirall’s Tudorza Pressair aclidinium bromide dry powder inhaler for the maintenance treatment of COPD is now available in the United States, where it is being marketed by Forest Laboratories. The twice-daily anticholinergic was approved in… Read more . . .
-
Aptar Pharma has announced the selection of a customized Landmark dose indicator for Skyepharma’s Flutiform fluticasone propionate/formoterol fumarate MDI. Flutiform is available for the treatment of asthma in Germany, the UK, and several other countries.… Read more . . .
-
The US Patent and Trademark Office has issued Patent number 8,324,266, titled “Compositions, Methods & Systems for Respiratory Delivery of Two or More Active Agents,” to Pearl Therapeutics. The patent covers formulation methods using the… Read more . . .
-
According to Consort Medical, Nicoventures, a subsidiary of the British American Tobacco Group, has awarded a contract to Consort’s Bespak Division “for the supply of an innovative nicotine inhalation product for use as a safer… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden